Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 19, 2017
Pharmacy Choice - Pharmaceutical News - FDA hits the ground running with 12 first-quarter 2017 drug approvals [Syrian Arab News Agency] - September 19, 2017

Pharmacy News Article

 4/20/17 - FDA hits the ground running with 12 first-quarter 2017 drug approvals [Syrian Arab News Agency]

After a big slowdown in 2016, FDA new drug approvals got off to a hot start in 2017. During the first quarter, the regulator signed off on more new meds than during the same period of any year in recent history.

So far this year, the agency has endorsed 13 new drugs, including blockbusters-to-be Ocrevus from Roche and Dupixent from partners Sanofi and Regeneron.

With 12 new drugs approved in the first quarter, FDA approval action this year bested any since 2011, according to the FDAs website. In recent years, the agency has signed off on between 6 and 10 new drugs in the first quarter.

Notable approvals this year are Roches multiple sclerosis med Ocrevus, which the drugmaker priced at a discount to reverse the trend of growing MS drug prices, and Sanofi and Regenerons atopic dermatitis med Dupixent. The pharma giants will now put their formidable sales forces behind the products, which are expected to be the biggest launches this year.

Another drug expected to make its U.S. debut with a 2017 FDA approval is PTC Therapeutics Emflaza, a decades-old steroid thats been mired in a pricing scandal since Marathon Pharma ushered the med through the regulatory process. Facing pricing backlash thanks to an $89,000 sticker price, Marathon offloaded the drug to PTC, which hasnt announced a new price.

Itll be hard for the FDA to maintain the fast pace, as Regulatory Focus reports that the agency has about 20 new drug and biologics applications pending for the year, citing BioPharmCatalysts PDUFA calendar.

In addition to the approvals, there has been a notable denial. The agency turned away Eli Lillys much-anticipated rheumatoid arthritis med baricitinib last week, asking for additional clinical data to ensure appropriate dosing and safety. Baricitinib, a once-daily oral option for moderate-to-severe rheumatoid arthritis, is expected to reach $1.8 billion in sales by 2022.

The first-quarter uptick comes after approvals nosedived last year with just 22 meds given the green light. That compared to 2014 and 2015, when the FDA approved 41 and 45 new meds, respectively.



(c) International 2006-2017, SANA Provided by SyndiGate Media Inc. (Syndigate.info).

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Sep 20: What's New? New Treatments for Type 2 Diabetes
Last Chance
Sep 21: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Sep 22: Influenza 2017-2018: An Update on Prevention and Treatment
Sep 24: Using Effective Communication to Reduce Medication Errors
Sep 25: Management of Major Depressive Disorders
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415